Comparative study on the clinical efficacy and safety of the Alrex (0.2% Lotemax) and Patalo (0.1% olopatadine hydrochloride) treatment of seasonal allergic conjunctivitis (SAC)
Latest Information Update: 26 Dec 2017
At a glance
- Drugs Loteprednol etabonate (Primary) ; Olopatadine
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- 26 Dec 2017 New trial record